Overview

National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis

Status:
NOT_YET_RECRUITING

Trial end date:
2031-12-01

Target enrollment:

Participant gender:

Summary

Chronic liver disease is a growing health concern, with limited access to liver transplants. This study addresses the urgent need for alternatives by exploring regenerative therapies, like G-CSF, to boost the liver's natural repair. The goal is to develop safe, effective, and accessible treatments for patients who cannot undergo transplant.

Phase:

Details

Lead Sponsor:

Institute of Liver and Biliary Sciences, India

Collaborator:

Indian Council of Medical Research

Treatments:

Darbepoetin alfa
Granulocyte Colony-Stimulating Factor